Roche acquires Stratos Genomics to further develop DNA based sequencing » 06:0905/2205/22/20
Roche announced that it…
Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche's nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion, Roche said in a statement. "Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients," said Thomas Schinecker, CEO Roche Diagnostics. "We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche." Stratos Genomics will continue operations in Seattle, Washington, U.S. Financial details of the agreement were not disclosed.
|Over a week ago|
Roche: Elecsys Anti-SARS-CoV-2 antibody test live at more than 20 U.S. sites » 16:2805/1905/19/20
Roche announced its…
Roche announced its Elecsys(R) Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout the United States, with plans in the next several weeks to increase to more than 200 commercial and hospital lab sites with the ability to perform millions of tests per week. The Elecsys Anti-SARS-CoV-2 antibody test received Emergency Use Authorization from the FDA earlier this month
Roche announces fifth indication for Tecentriq in lung cancer approved by FDA » 15:3205/1805/18/20
Genentech, a member of…
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Tecentriq as a first-line treatment for adults with metastatic non-small cell lung cancer, or NSCLC, whose tumors have high PD-L1 expression, as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, said, "Today marks the fifth approval of Tecentriq in lung cancer, as we remain committed to providing an effective and tailored treatment option for every person diagnosed with this disease." In the U.S., Tecentriq has received four approvals across NSCLC, including as a single agent or in combination with targeted therapies and/or chemotherapies. It is also approved in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer.
Roche price target raised to CHF 395 from CHF 385 at Barclays » 12:5905/1505/15/20
Barclays analyst Emmanuel…
Barclays analyst Emmanuel Papadakis raised the firm's price target on Roche to CHF 395 from CHF 385 and keeps an Overweight rating on the shares.
Allogene jumps, Compugen plunges following release of cancer meeting abstracts » 12:5105/1405/14/20
MEIP, SGEN, EXEL, MGNX, CGEN, INO, ALLO, MRK, RHHBY
On Wednesday after market…
Arcus Biosciences price target raised to $40 from $22 at Mizuho » 06:4305/1405/14/20
Mizuho analyst Mara…
Mizuho analyst Mara Goldstein raised the firm's price target on Arcus Biosciences (RCUS) to $40 from $22 and keeps a Buy rating on the shares. The analyst sees Roche's (RHHBY) tiragolumab data as validation of the synergistic mechanism of the doublet of anti-TIGIT plus PD-(L)1 inhibition, which Arcus is exploring via AB154. The new price target reflects an added probability of success of 50% for AB154.
Roche upgraded to Outperform from Peer Perform at Wolfe Research » 09:3005/1305/13/20
Wolfe Research analyst…
Wolfe Research analyst Timothy Anderson upgraded Roche to Outperform from Peer Perform with a price target of CHF 410, up from CHF 343. While he is not changing his estimates, he has raised his multiple to reflect his view of the company's pipeline and expectation for upward revisions to the outlook.
Roche upgraded to Outperform from Peer Perform at Wolfe Research » 05:4805/1305/13/20
Wolfe Research analyst…
Wolfe Research analyst Timothy Anderson upgraded Roche to Outperform from Peer Perform with a CHF 410 price target.
Roche announces launch of new KAPA Target Enrichment portfolio » 10:0305/1205/12/20
Roche announced the…
Roche announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target enrichment solutions for sequencing. "KAPA HyperExome is a whole exome research panel with significantly improved performance over the existing on-market SeqCap portfolio and other products on the market. In addition to the Target Enrichment portfolio, Roche is also launching the new HyperDesign tool that enables researchers to create custom target enrichment designs that utilize the new KAPA HyperChoice probes. The probes are paired with a streamlined, automatable workflow," the company said.
Jefferies medtech analysts to hold an analyst/industry conference call » 12:2505/0805/08/20
ABT, BDX, BIO, CPHD, DGX, HOLX, LH, RHHBY
MedTech Analysts Petrone…
MedTech Analysts Petrone & Denhoy, along with Key Opinion Leader Dr. Babkowski, Laboratory Medical Director at Stamford Hospital, discuss COVID-19 testing and point-of-care settings (companies of interest: ABT BDX BIO CPHD HOLX LH RHHBY) on an Analyst/Industry conference call to be held on May 8 at 1 pm.